Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kava Labeling Revisions Adopted By Trade Groups; FDA Issues Advisory

This article was originally published in The Tan Sheet

Executive Summary

Various dietary supplement trade associations adopted revised kava labeling requirements for their member companies following the release of an 1FDA consumer advisory on the botanical
Advertisement

Related Content

Echinacea Is Leading Natural Remedy In NIH/CDC Survey On CAM Use
Kava fatalities in MMWR
FDA Intervention In Kava Labeling Suit Sought By Jarrow Formulas
Chaparral AER Data Resembles Kava Reports, CRN’s Cardellina Says
Chattem Exiting Ephedra Market With Dexatrim Reformulations
Three-Step Supplement Safety Review Model Proposed by IoM
USP Releases Horse Chestnut Monographs, Kava Revisions
WHO CAM Strategy Advocates Creation Of National Policies, Increased R&D
Kava, Valerian Effects On Anxiety, Insomnia Similar To Placebo – Online Trial
Kava Removed From UK Market; FDA Contacts Healthcare Community

Topics

Advertisement
UsernamePublicRestriction

Register

PS093824

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel